RET Fusion+ mNSCLC

Updated data in RET fusion+ metastatic non–ؘsmall-cell lung cancer and insights on approaching testing for RET fusions.

Data from the following clinical trials are discussed:

• Selpercatinib (LOXO-292) in patients with RET-fusion+ non–small cell lung cancer. (Goto K et al. 2020 ASCO annual meeting. Abstract 3584.)

• Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non–small cell lung cancer patients on the LIBRETTO-001 trial. (Subbiah V et al. 2020 ASCO annual meeting. Abstract 9516.)

• Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients with advanced RET fusion+ non–small cell lung cancer. (Gainor JF et al. 2020 ASCO annual meeting. Abstract 9515.)